TiumBio CEO On Successful Partnerships, Ambitions To Develop The Next Afstyla
Multiple Clinical Assets Progressing
Executive Summary
TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.